论文部分内容阅读
目的 实验观察表皮生长因子受体单克隆抗体(EGFR McAb)egf/r3对肺癌的治疗作用。方法 体外细胞增殖抑制实验采用MTT法,裸鼠体内移植瘤采用同时治疗(T1组)与延后治疗(T2组)两种方案。结果 egf/r3 McAb对高表达EGFR的SPC-A1 和A549 肺癌细胞体外均具有增殖抑制作用,并呈剂量依赖性;以SPC-A1 进行裸鼠皮下移植做体内实验,至治疗结束,T1 组50 % 成瘤(3/6),对照组100 % 成瘤(6/6);至实验结束,T1组与T2 组瘤体抑制率分别为75 % 与67 % ,瘤重抑制率分别为65 % 与47 % 。病理切片显示治疗组肿瘤组织局部坏死,电镜示线粒体凝缩、嵴断裂、溶解。结论 egf/r3 McAb 部分抑制肺癌细胞成瘤,明显延缓已成瘤肺癌生长,具有一定的抗肺癌作用。其体内抗瘤效果强于体外,可能与宿主免疫系统参与瘤细胞溶解有关
Objective To observe the therapeutic effect of epidermal growth factor receptor monoclonal antibody (EGFR McAb)egf/r3 on lung cancer. Methods MTT assay was used to inhibit cell proliferation in vitro. In nude mice, the two groups were treated simultaneously (T1 group) and delayed treatment (T2 group). RESULTS: The egf/r3 McAb inhibited the proliferation of SPC-A1 and A549 lung cancer cells with high expression of EGFR in vitro in a dose-dependent manner. The subcutaneous transplantation of SPC-A1 in nude mice was performed in vivo until the end of treatment. T1 group 50 % tumor formation (3/6), control group 100% tumor formation (6/6); by the end of the experiment, tumor inhibition rates were 75% and 67% in T1 and T2 groups, respectively, and tumor weight inhibition rates were 65%. With 47%. Pathological sections showed local necrosis in the treated group. Electron microscopy showed mitochondrial condensing, sacral breakage, and dissolution. Conclusion egf/r3 McAb partially inhibits the tumorigenesis of lung cancer cells and significantly retards the growth of tumor-bearing lung cancer, which has a certain anti-lung cancer effect. Its anti-tumor effect in vivo is stronger than in vitro, and may be related to the involvement of the host immune system in tumor cell lysis.